Granahan Investment Management Inc. MA Takes $14.57 Million Position in Teladoc Inc (TDOC)

Granahan Investment Management Inc. MA purchased a new position in Teladoc Inc (NYSE:TDOC) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 439,501 shares of the health services provider’s stock, valued at approximately $14,569,000. Teladoc makes up approximately 1.2% of Granahan Investment Management Inc. MA’s portfolio, making the stock its 19th biggest holding. Granahan Investment Management Inc. MA owned 0.77% of Teladoc at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in TDOC. Rosenblum Silverman Sutton S F Inc. CA grew its holdings in shares of Teladoc by 2.7% during the second quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 67,395 shares of the health services provider’s stock worth $2,339,000 after buying an additional 1,800 shares in the last quarter. Bank of Montreal Can grew its holdings in shares of Teladoc by 214.2% during the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock worth $123,000 after buying an additional 2,397 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Teladoc by 66.3% during the first quarter. Legal & General Group Plc now owns 6,137 shares of the health services provider’s stock worth $154,000 after buying an additional 2,446 shares in the last quarter. Raymond James Trust N.A. grew its holdings in shares of Teladoc by 36.2% during the third quarter. Raymond James Trust N.A. now owns 9,943 shares of the health services provider’s stock worth $330,000 after buying an additional 2,643 shares in the last quarter. Finally, American International Group Inc. grew its holdings in shares of Teladoc by 8.1% during the third quarter. American International Group Inc. now owns 36,079 shares of the health services provider’s stock worth $1,196,000 after buying an additional 2,697 shares in the last quarter.

In other news, VP Mark Hirschhorn sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $31.93, for a total value of $798,250.00. Following the completion of the sale, the vice president now directly owns 64,987 shares of the company’s stock, valued at $2,075,034.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Jason N. Gorevic sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $32.10, for a total value of $642,000.00. Following the completion of the sale, the chief executive officer now directly owns 838,261 shares of the company’s stock, valued at $26,908,178.10. The disclosure for this sale can be found here. Insiders have sold 265,000 shares of company stock valued at $8,697,400 over the last three months. Insiders own 4.47% of the company’s stock.

A number of research firms recently issued reports on TDOC. Deutsche Bank began coverage on Teladoc in a report on Friday. They set a “buy” rating and a $39.00 price objective for the company. KeyCorp reiterated a “buy” rating and set a $39.00 price objective on shares of Teladoc in a report on Monday, December 4th. CIBC reiterated an “outperform” rating and set a $45.00 price objective (up from $40.00) on shares of Teladoc in a report on Tuesday, November 21st. Oppenheimer increased their price objective on Teladoc from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Tuesday, November 21st. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $31.00 price objective on shares of Teladoc in a report on Monday, November 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $39.15.

Shares of Teladoc Inc (NYSE:TDOC) traded down $0.20 during midday trading on Monday, reaching $33.55. The company had a trading volume of 1,198,500 shares, compared to its average volume of 970,639. Teladoc Inc has a 1 year low of $15.65 and a 1 year high of $37.90. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.83.

Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.25). Teladoc had a negative net margin of 39.61% and a negative return on equity of 21.59%. The company had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. During the same period last year, the company posted ($0.33) earnings per share. The business’s revenue for the quarter was up 112.0% on a year-over-year basis. equities research analysts anticipate that Teladoc Inc will post -1.57 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/12/11/granahan-investment-management-inc-ma-takes-14-57-million-position-in-teladoc-inc-tdoc.html.

Teladoc Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Inc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply